Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on GLOBAL BIOENERGIES SA. We currently have 8 research reports from 1 professional analysts.
Frequency of research reports
Research reports on
GLOBAL BIOENERGIES SA
GLOBAL BIOENERGIES SA
String of successes and new financing
18 Nov 16
Global Bioenergies (GBE) has delivered a string of industrial and commercial successes, with completion of construction at the Leuna plant, more progress on second-generation feedstock development and new potential clients. It has secured significant new financing and delivered reasonable H1 results. Our valuation remains unchanged at €37-56/share.
Opening the next chapter
29 Jun 16
GBE has delivered impressive progress on its alternative olefins production technology. It is now entering the final phase of industrialisation and on the verge of commercialisation. Low oil prices make for a difficult business environment, but efforts by management to diversify away from the oil-related market could help to reduce the oil price dependence. Nevertheless, there is immediate commercial market potential for GBE. Our core valuation range is €37-56 per share.
Spend to deliver
08 Apr 16
Global Bioenergies (GBE) is scaling up its operations as planned ahead of its next important steps to commercialisation. 2015 results are evidence of managed expenses, while capex spend is peaking as the company builds its second demo plant. GBE has also achieved further improvement in isobutene purity, which opens new, higher value-added end markets. We believe the company is on track with its operations and funded through to 2017. Our valuation range remains unchanged at €32-59 per share.
29 Jan 16
Global Bioenergies (GBE) has raised €6.5m in a private placement, lifting its gross cash to €16m to fund its isobutene process development and commercial roll-out. This should fund the company well into 2017 and even cover some increased outlay for more aggressive commercial development. Our updated model results in a fair value range of €32-59 per share (from €35-63).
Step forward ahead of schedule
18 Dec 15
Global Bioenergies (GBE) has delivered another step on its road towards bringing its isobutene process to industrial scale with the installation of the central fermenter at its Leuna plant. This is important preparation for commercial scale. We anticipate the company will aim to develop end-markets that are uncorrelated to oil while a weak oil price prevails. Our fair value remains unchanged at €35-63 per share.
On the road to commerciality
24 Sep 15
Global Bioenergies’ H1 results demonstrate good operational execution and strong cash control. The company’s current cash allows for capital spend well in line with our expectations. We note further operational progress with additional process adaptation to second-generation sucrose feedstocks. Our DCF-based valuation range remains €35-63 per share.
01 Nov 16
Since our last outlook note, Quadrise has begun to supply MSAR for extended LONO sea trials, paving the way for commercial adoption from calendar H217 onwards. In August it signed a memorandum of understanding with clients in the Kingdom of Saudi Arabia (KSA), which is a key enabler for progressing the production-to-combustion pilot there. In October it completed a placing and open offer raising a total of £5.25m (gross). This should enable it to transition comfortably to the commercial phase on successful completion of the LONO and KSA trials.
GTL transaction not going ahead
01 Dec 16
Intelligent Energy (IEH) has announced that the deal to acquire the Energy Management Business of GTL will not now be consummated. The move leaves management free to concentrate on driving sales of commercially ready B2B products, which is a key element of its strategy. We adjust our FY17e revenue estimate while leaving our pre-exceptional losses and cash-flow forecasts unchanged.
GMP FirstEnergy ― UK Energy morning research package
30 Nov 16
Gran Tierra (GTE CN)1, 6; BUY, C$5.50: Equity financing and acquisition of two blocks from Ecopetrol | Northern Petroleum (NOP LN)1; SPECUATIVE BUY, £0.15: Farm out and equity issue | President Energy (PPC LN) (not covered): IFC Equity Subscription | Primeline Energy (PEH CN) (not covered): 2Q16 Results ended 30 September 2016 | Faroe Petroleum (FPM LN)6 ; BUY, £1.20: Oda update in Norway | Jersey Oil & Gas (JOG LN)1 ; Under Review: Placing | SacOil (SAC LN/SCL SJ)1 : SPECULATIVE BUY, £0.016, Trading Update
24 Nov 16
Quixant* (QXT): Gaming gains (CORP) | SCISYS* (SSY): Bringing good news from Germany (CORP) | Hayward Tyler Group*: Contract wins (CORP) | Sound Energy (SOU): TE-7 flow rate and fund raise (BUY) | Water Intelligence* (WATR): Growth and improving returns in a defensive market (CORP) | Imaginatik* (IMTK): Interim trading update (CORP)
30 Nov 16
Abzena (ABZA): Interim results indicate happy customers (BUY) | Horizonte Minerals* (HZM): Fund raise completed (CORP) | SacOil* (SAC): Half-year trading statement (CORP) | Revolution Bars (RBG): New openings (BUY) | Amino Technologies* (AMO): Multi operator FUSION roll out (CORP)
Operating profits and net cash position – restored; market outlook – precarious
01 Dec 16
The turnaround was noticeable Lonmin’s full-year (September-ending) results were ahead of consensus and AV’s estimates. Sales came in at $1.1bn (-14% yoy) as the average realised (USD-denominated) PGM prices and sales volumes were down yoy 12% and 2%, respectively. However, platinum sales (736koz) were much ahead of earlier guidance (700koz) – thanks to certain smelting/processing efficiencies, which helped more than offset the impact of reorganisation-related disruptions. After two consecutive years (FY14-15) of hefty operating losses, Lonmin finally reported an adjusted operating profit (even though feeble) of $7m. This was facilitated by the record weakness in the South African rand (down from ZAR12/$ in FY15 to ZAR14.77/$ in FY16) and ZAR1.3bn of cost savings – 86% higher than the earlier target. Disappointingly, Lonmin recognised $335m of asset impairments (vs. $1.8bn in FY2015), which resulted in a full-year net loss of $400m. But the turnaround in reported OCFs – inflow of $58m vs. an outflow of $12m – was a much-needed improvement, which, along with conservative capex (-35% yoy) of $87m, resulted in a net cash position of $173m (with no short-term repayments) vs. a net debt position of $185m (at end-FY15). But the guidance spells caution For FY17, management targets conservative platinum sales of 650-680koz, while unit costs are expected to remain under pressure – ZAR10,800-11,300/oz vs. ZAR10,748/oz achieved in FY16. On the other hand, capex plans would be aggressive – ZAR1.8bn (which includes ZAR400m for the tailings project – already delayed by almost two years) vs. ZAR1.3bn spent in FY16.